Immatics N.v. · NASDAQ:IMTX
Immatics — Investor Presentation (November 2024)
83 slides from Immatics's investor presentation, Nov 8, 2024
Slide 1: Immatics Corporate Presentation
Delivering the Power of T cells to Cancer Patients © Immatics. Not for further reproduction or distribution. Immatics Corporate Presentation November 8, 2024
Slide 2: Forward-Looking Statement
Forward - Looking Statement This presentation (“Presentation”) is provided by Immatics N . V . (“Immatics” or the “Company”) for informational purposes only . The information contained herein does not purport to be all - inclusive and none of Immatics, any of its affiliates, any of its or their resp
Slide 3: Building a Leading TCR Therapeutics Company
Therapeutic Op p o rt u n ity Potential for addressing large patient populations with high prevalence targets in solid tumors Two Clinical - Stage Modalities Pipeline of TCR - T and TCR Bispecific product candidates in clinical & preclinical development Building a Leading TCR Therapeutics Company 3
Slide 4: 2024 ACTengine and TCER Clinical Milestones
2024 ACTengine® and TCER® Clinical Milestones 4 • Targeted randomized Phase 3 trial for ACTengine® IMA203 in 2L+ melanoma in 2024 • Clinical data update from Phase 1b dose expansion trial at SMR Conference on Oct 11, 2024; IMA203CD8 (GEN2) update at SITC Conference on Nov 9, 2024 ACTengine® IMA203 /
Slide 5: Two Distinct TCR-based Therapeutic Modalities in Clinical Development
Two Distinct TCR - based Therapeutic Modalities in Clinical Development 5 Differentiated positioning of ACTengine® vs. TCER® based on patient population and medical need I n t r o 1 Interim data update from the ACTengine® IMA203 and IMA203CD8 monotherapies (published November 8, 2024) TCR Bispecific
Slide 6: Our Pipeline of TCR-based Adoptive Cell Therapies and Bispecifics
Our Pipeline of TCR - based Adoptive Cell Therapies and Bispecifics 6 1 Phase 1a: Dose escalation, Phase 1b: Dose expansion; 2 Immatics’ proprietary ACTallo® platform utilizing Editas’ CRISPR gene editing technology; 3 mRNA - enabled in vivo expressed TCER® molecules Phase 3 Phase 2 Phase 1b 1 Phase
Slide 7: Realizing the Full Multi-Cancer Opportunity of PRAME
Realizing the Full Multi - Cancer Opportunity of PRAME ACTengine® IMA203 (TCR - T) and TCER® IMA402 (TCR Bispecific) 7 A C T en g i ne® IMA203 (TCR - T) Cancer Cell Death PRAME is one of the most promising and most prevalent, clinically validated solid tumor targets known to date Leverage the full p
Slide 8: ACTengine IMA203 – TCR-T Targeting PRAME
ACTengine® IMA203 – TCR - T Targeting PRAME 8
Slide 9: The Multi-Cancer Opportunity of PRAME
The Multi - Cancer Opportunity of PRAME One of the Most Promising Solid Tumor Targets for TCR - based Therapies Known To Date 9 High prevalence High target density Homogeneous expression “Clean” expression profile Clinical proof - of - concept s qNSC L C Ovarian Cancer PRAME fulfills all properties
Slide 10: IMA203 TCR-T Has the Potential to Reach a Large Patient Population
Patient Population PRAME Positive R/R Incidence Incidence Selected Indications Based on R/R Incidence; PRAME and HLA - A*02:01+ 2,999 95% 7,700 99,800 Cut. Melanoma 292 89% 800 1,500 Uveal Melanoma 4,408 84% 12,800 19,900 Ovarian Carcinoma 4,255 97% 10,700 62,700 Uterine Carcinoma 779 100% 1,900 3,3
Slide 11: ACTengine IMA203 Targeting PRAME – Mechanism of Action
ACTengine® IMA203 Targeting PRAME – Mechanism of Action Immatics’ a ing - T Approach 11 I MA2 0 3 LEUKAPHARESIS
Slide 12: ACTengine IMA203 TCR-T Product Manufacturing
ACTengine® IMA203 TCR - T Product Manufacturing Differentiated Manufacturing Process and Setup 1 - week manufacturing process followed by 1 - week QC release testing High manufacturing success rate of >95% to reach IMA203 targ t os Lean and cost - efficient process Proprietary Manufacturing Process
Slide 13: ACTengine IMA203 TCR-T Monotherapy – Patient Flow
ACTengine® IMA203 TCR - T Monotherapy – Patient Flow HLA - A*02 Testing Blood sample; Central lab Treatment & Observation Phase Long Term Follow - up Screening & Manufacturing Phase Manufacturing by Immatics Infusion of ACTengine® IMA203 TCR - T Product Lymphodepletion * Low dose IL - 2 ** Safety an
Slide 14: ACTengine IMA203 TCR-T Trial in Melanoma
ACTengine® IMA203 TCR - T Trial in Melanoma Heavily Pretreated Patient Population Data cut - off Aug 23, 2024 14 1 See patient flow in appendix. 2 All infused patients; *Cutaneous melanoma patients had a median of 2 prior lines of checkpoints, see appendix; RP2D: recommended phase 2 dose; CPI: Check
Slide 15: Most Frequent Adverse Events of IMA203
15 Data cut - off Aug 23, 2024 • Most frequent adverse events were expected cytopenias (Grade 1 - 4) associated with lymphodepletion in all patients • Mostly mild to moderate cytokine release syndrome (CRS) • 37% (26/70) Grade 1 • 46% (32/70) Grade 2 • 11% (8/70) Grade 3 2 • Infrequent ICANS (6% Gra
Slide 16: Tolerability Profile of IMA203 Across All Dose Levels
Tolerability Profile of IMA203 Across All Dose Levels in Phase 1a/b ll ≥Gra 3 v rs v nts (N=70 1 ) TEAEs by maximum severity for all patients in Phase 1a and Phase 1b (N=70 1 ) Data cut - off Aug 23, 2024 16 ≥ Gra 3 Adverse event ( System organ class , Preferred term) % No. 100.0 70 Patients with an
Slide 17: Best Overall Response for IMA203 in Melanoma
Best Overall Response for IMA203 in Melanoma Objective Responses in Heavily Pretreated Patients in Phase 1b (N=28 # ) Data cut - off Aug 23, 2024 17 ongoi n g # First tumor assessment post infusion pending for two melanoma patients at data - cut; * Maximum change of target lesions and RECIST1.1 resp
Slide 18: Response Over Time of IMA203 in Melanoma
Response Over Time of IMA203 in Melanoma Durable Responses 2 Years+ after Treatment in Heavily Pretreated Patients in Phase 1b (N=28 # ) 18 Ongoing Scans at approximately week 6, month 3 and then every 3 months Data cut - off Aug 23, 2024 # First tumor assessment post infusion pending for two melano
Slide 19: Significant Shift in PFS and OS Between Dose Escalation & Expansion
Significant Shift in PFS and OS Between Dose Escalation & Dose Expansion PFS of 6 Months and OS Not Reached in Melanoma Efficacy Population 19 Progression Free Survival Data cut - off Aug 23, 2024 Overall Survival Overall survival (OS) and progression - free survival (PFS) censored at data - cut; *
Slide 20: IMA203 Phase 1b in Melanoma: Overview of Studies
IMA203 Phase 1b in Melanoma: Overview of Studies PFS and OS Data in 2L+ Melanoma Cohorts mOS (months) mPFS (months) Prior lines of therapies 2L+ melanoma patient population N Phase Drug Product not reached 6.0 4% n=0, 18% n=1, 32% n=2, 29% n=3:, 4% n=4, 11% n=5, 4% n=6 86% received prior CPI (median
Slide 21: Enhanced PFS in Phase 1b Melanoma Patients with Deep Responses
Enhanced PFS in Phase 1b Melanoma Patients with Deep Responses N=26 # 21 • Approx. half of all patients have a deep response (>50% tumor reduction) • This subgroup of patients has highly medically meaningful mPFS of more than 1 year • Patients with <50% tumor reduction (including tumor size increase
Slide 22: Dose Response Relationship
0 5 î 10 5 1 î 10 6 1.5 î 10 6 2 î 10 6 2.5 î 10 6 Cmax (vector copies/μg gDNA) 4 6 8 10 Infused Total (CD8 + Dex + ) IMA203 T cell dose (x10 9 ) 2 1 0 Dose Response Relationship IMA203 T Cell Dose is Associated with Clinical Activity and IMA203 T Cell Exposure (N=65 out of 68*) 22 RP2D cPR (n=23) P
Slide 23: Exposure Response Relationship
Exposure Response Relationship IMA203 T Cell Persistence Over Time and T Cell Exposure is Associated with Clinical Response 23 Rapid T cell engraftment (C max ) in all patients with over two years of persistence Higher C max and persistence in patients treated at higher doses in dose expansion versu
Slide 24: Patient Case: Cutaneous Melanoma
Patient Case A - DL4 - 03 : Cutaneous Melanoma 24 Images courtesy of treating physician (Dr. Martin Wermke, University of Dresden) PET - based Complete Response 15 Months Post Infusion and Ongoing Response at 24 Months 51 - year - old male patient with complete remission according to PET imaging aft
Slide 25: SUPRAME: Registration-enabling Randomized Phase 3 Trial
SUPRAME: Registration - enabling Randomized Phase 3 Trial Trial Design Following Recent Type D Meeting with FDA and SA Meeting with PEI 1 25 ACTengine® IMA203 N=180 Investigator’s choice of selected approved treatments N=1 8 0 Endpoints • Primary Endpoint • PFS • Secondary Endpoints • Safety • ORR +
Slide 26: Combining IMA203 TCR-T with mRNA Cancer Vaccine – Patient Flow
Combining Immatics’ - h ra y with o rna’s m N anc r Vaccin 26 HLA - A*02 testing Blood sample; Central lab Treatment & Observation Phase (1 year) F ollo w - u p (2 years) Screening & Manufacturing Phase Manufacturing by Immatics Infusion of ACTengine® IMA203 TCR - T Product Lymphodepletion * mRNA/LN
Slide 27: IMA203 Monotherapy in Melanoma: Summary of Clinical Data
ACTengine® IMA203 TCR - T Monotherapy Targeting PRAME in Melanoma Summary of Clinical Data Tolerability PFS & OS Biological Data Broad Reach Favorable tolerability profile: mostly mild to moderate CRS; infrequent ICANS (5.7% Gr1, 4.3% Gr2, 4.3% Gr3); no treatment related deaths Anti - Tumor Activity
Slide 28: High Unmet Medical Need in Cutaneous and Uveal Melanoma
28 High Unmet Medical Need in Cutaneous and Uveal Melanoma Clinically and Commercially Attractive Features of IMA203 Uveal Melanoma Cutaneous Melanoma Kim m t r a k - r e f r a c t o r y , CPI/chemotherapy - refractory 2L+ CPI - refractory, BRAF/MEK inhibitor - refractory if BRAF mutation+ 2L+ Patie
Slide 29: IMA203CD8 GEN2 – Leveraging CD8 and CD4 Cells
IMA203CD8 GEN2 – IMA203 TCR - T Monotherapy Leveraging CD8 and CD4 cells Differentiated Pharmacology Compared to 1 st - Generation TCR - only Approaches • IMA203CD8 (GEN2) designed to broaden the clinical potential of IMA203 TCR - T monotherapy by adding functional CD4 T cells via co - transduction
Slide 30: IMA203CD8 (GEN2) – Preclinical Assessment of Anti-Tumor Efficacy
IMA203CD8 (GEN2) – Preclinical Assessment of Anti - Tumor Efficacy Functional CD4 T cells Mediate Longer Anti - Tumor Activity than CD8 T cells in vitro 30 1 .0 1 .5 2 .0 CD 8 0.5 0.0 0 50 100 150 200 250 300 350 400 450 Hours after Coculture Tumor fold growth 2 nd addition of tumor cells 3 rd 4 th
Slide 31: IMA203CD8 (GEN2) – Overview of Patient Characteristics
1 DL4a cleared in Dec 2023; 2 DLTs at DL4b triggered modifications of the eligibility criteria, adapted patient population is treated with DL4c; 3 All patients who started lymphodepletion. 4 All infused patients with at least one tumor assessment postbaseline. Data cut - off Sep 30, 2024 31 IMA203CD
Slide 32: Tolerability Data – IMA203CD8 (GEN2)
Tolerability Data – IMA203CD8 (GEN2) ll ≥Gra 3 v rs v nts (N=44) Data cut - off Sep 30, 2024 32 IMA203CD8 … tabl continu 100.0 44 Patients with any adverse event 9.1 4 Immune system disorders 15.9 7 Adverse events of special interest 9.1 4 Haemophagocytic lymphohistiocytosis 2 13.6 6 Cytokine releas
Slide 33: IMA203CD8 – Best Overall Response in Dose Escalation
IMA203CD8 (GEN2) (N=41) – Best Overall Response in Dose Escalation Data cut - off Sep 30, 2024 Data cut - off Sep 30, 2024 33 IMA203CD8 41% (14/34) c O R R 9.2 months 2.0+, 23.5+ 13.1 months median DOR (min, max) m FU 10/17 responses ongoing including 3 confirmed responses at 1+ year D r s ons s wit
Slide 34: IMA203CD8 – Response over Time in Dose Escalation
IMA203CD8 (GEN2) (N=41) – Response over Time in Dose Escalation Data cut - off Sep 30, 2024 Data cut - off Sep 30, 2024 34 IMA203CD8 1 Metabolic CR according to PET - CT 2 Patients off study at data - cut; 3 three patients excluded from tumor shrinkage analysis and figures due to lack of post - trea
Slide 35: IMA203CD8 (GEN2): Translational Data Shows Enhanced Pharmacology
IMA203CD8 (GEN2): Translational Data Shows Enhanced Pharmacology IMA203 Phase 1b vs IMA203CD8 (GEN2) 35 Trend towards responses at lower cell dose and higher tumor burden with IMA203CD8 Higher peak expansion (C max ) of IMA203CD8 T cells when normalized to infused dose Higher activation levels in IM
Slide 36: Opportunity of IMA203CD8 in Medium-level PRAME Expressing Indications
Opportunity of IMA203CD8 in Medium - level PRAME Expressing Indications 36 * Patients treated at RP2D during Ph1b with evaluable post baseline assessments at data - cut off IMA203: Aug 23, 2024 IMA203CD8 PRAME expression level associates with clinical activity in IMA203 and IMA203CD8 treated patient
Slide 37: Patient Case DL4b-04: Synovial Sarcoma
Non - target Lesions Target Lesions Baseline Follow - up Month 12, - 100% reduction 24 - year - old male patient with complete remission according to PET imaging after 14 months post infusion • 1 prior systemic treatment line: Doxorubicin + Ifosfamide + Mesna • 3 years of cancer history • At BL: 33.
Slide 38: Summary of IMA203CD8 Clinical Data and Planned Next Steps
ACTengine® IMA203CD8 (GEN2) TCR - T Monotherapy Targeting PRAME Summary of IMA203CD8 Clinical Data and Planned Next Steps 38 Data cut - off Sep 30, 2024 IMA203CD8 • Manageable tolerability with most frequent ≥Grade 3 AEs being expected cytopenia • DLTs in 2 patients at DL4b triggered dosing adjustme
Slide 39: Potential of IMA203 in Additional Solid Cancer Indications
PRAME mRNA expression in IMA203 (GEN1) (n=14) Data cut - off Aug 23, 2024 PRAME mRNA expression in IMA203CD8 (GEN2) responders (n=13) Data cut - off Sep 30, 2024 Potential of IMA203 in Additional Solid Cancer Indications 39 % PRAME - positive patients 1 PRAME target expression distribution (blue his
Slide 40: TCER – TCR Bispecifics
TCER® – TCR Bispecifics 40
Slide 41: TCER – Next-generation, Half-Life Extended Bispecifics
TCER® – Immatics’ N xt - generation, Half - Life Extended Bispecifics Proprietary TCER® Format Consisting of Three Distinct Elements 41 High - affinity TCR domains targeting XPRESIDENT® - selected tumor - specific peptide - HLA molecules L o w - a ffi n i t y T cell recruiter against CD3/TCR Fc part
Slide 42: TCER – Next-generation, Half-Life Extended Bispecifics
TCER® – Immatics’ N xt - generation, Half - Life Extended Bispecifics 42 pHLA targeting TCR x High - affinity (single digit nM) TCR targeting XPRESIDENT® - selected tumor - specific peptide - HLA molecules x Broad therapeutic window through XPRESIDENT® - guided affinity maturation (>1000x) 1 x Compl
Slide 43: Potency of Our Proprietary TCR Bispecific Format TCER
Potency of Our Proprietary TCR Bispecific Format TCER® 43 • Seven different TCR Bispecific formats were evaluated with a pHLA targeting TCR and the identical T cell recruiting antibody • TCER® format had higher combination of potency and specificity 2 than six alternative TCR Bispecific format desig
Slide 44: TCER Format Designed for Optimized Efficacy and Safety: Tumor Control
TCER® Format Is Designed for Optimized Efficacy and Safety Superior Tumor Control Using a Novel, Low - Affinity Recruiter 44 n = 6 mice/treatment group, n = 10 mice in vehicle group, 2 donors/group Dose : 0 . 025 mg/kg Proprietary, low - affinity T cell recruiting region demonstrates superior tumor
Slide 45: TCER Format: Reduced Recruiter-Mediated Cytokine Release
TCER® Format Is Designed for Optimized Efficacy and Safety Reduced Target - Unrelated Recruiter - Mediated Cytokine Release using a Low - Affinity Recruiter 45 T CE R® Whole blood cytokine release assay N=3 HLA - A*02 - positive donors N=16 cytokines tested, 4 exemplary cytokines shown
Slide 46: Our TCER Portfolio
Our TCER® Portfolio Broad Pipeline of Next - Gen Half - Life Extended TCR Bispecifics 46 T CE R® • PRAME peptide presented by HLA - A*02:01 • Start of clinical trial in Aug 2023, first clinical data expected 2H 2024 IMA402 Potential for addressing different indications and large patient populations
Slide 47: In Vivo Expressed TCER Molecules with Moderna
In Vivo Expressed TCER® Molecules Targeting Cancer - specific pHLA Targets ombining Immatics’ arg t an latforms with o rna’s m N chnology 47 Moderna Delivery of TCER® biologics through mRNA Immatics Proprietary cancer targets & TCR Bispecifics format mRNA - encoded TCER® molecule XPR E SIDENT® targe
Slide 48: TCER IMA401 Targeting MAGEA4/8
TCER® IMA401 Targeting MAGEA4/8 48
Slide 49: IMA401: Higher Target Density of MAGEA4/8 Peptide
TCER® IMA401 Targeting MAGEA4/8 Higher Target Density of MAGEA4/8 Peptide 49 MAGEA4 protein detection in tumor samples (IHC) 1 MAGEA4/8 target prevalences are based on TCGA and in - house data combined with a XPRESIDENT® - determined target individual MS - based mRNA expression threshold; qPCR - thr
Slide 50: IMA401 – Anti-Tumor Activity in vivo Patient-Derived Tumor Model
TCER® IMA401 (MAGEA4/8) – Assessment of Anti - Tumor Activity in vivo Patient - Derived Tumor Model 50 NSCLC adenocarcinoma: • Male, Caucasian, age 58, no therapy prior to surgery • Site of origin: lung, differentiation poor • Date of surgery: 1987, Freiburg Medical Center • Volume doubling time: 7.
Slide 51: IMA401-101 Phase 1a Dose Escalation Trial Design
51 180 µg 540 µg 1800 µg 2500 µg Key Eligibility Criteria Object iv es Primary: • Determine MTD and/or RP2D Secondary: • Tolerability • Pharmacokinetics • Initial anti - tumor activity • Recurrent and/or refractory solid tumors • HLA - A*02:01 positive • MAGEA4/8 - positive as confirmed by mRNA - b
Slide 52: Baseline Characteristics
Baseline Characteristics Heavily Pre - treated Patients with a Broad Range of Tumor Types 52 1 Efficacy Analysis Set (EAS) prospectively defined in the study protocol: patients who received at least four IMA401 infusions and had at least one post - baseline efficacy assessment or clinical progressio
Slide 53: IMA401 Demonstrates Manageable Tolerability in N=35 Patients
53 IMA401 Demonstrates Manageable Tolerability in N=35 Patients Most Frequent Related AEs were Lymphopenia, CRS and Neutropenia ≥ Gra 3 All Grades TEAEs, n [%] 26 [74] 32 [91] Any 19 [54] 28 [80] Treatment - related ≥ Gra 3 All Grades Treatment - related AEs 1 , n [%] 11 [31] 12 [34] Lymphopenia 0 1
Slide 54: IMA401 Pharmacokinetics
IMA401 Pharmacokinetics TCER® Format Shows Extended Half - Life in Solid Cancer Patients 1 Half - lifes derived from 2nd PK profiles close to steady - state. Calculated by non - compartmental analysis (NCA) using Phoenix WinNonlin (Certara); Interquartile range (25% - 75% percentile): 13.5 - 22.2 da
Slide 55: Objective Responses are Associated with Target Expression
1 Patients in this analysis had received IMA401 infusions at ≥1 mg and showed MAGEA4/8 target expression above indicated MAGEA4/A8 high qPCR threshold (n=17); PD: Progressive disease; PR: Partial response; cPR: confirmed Partial response; SD: Stable disease. 55 Data cut - off Jul 23, 2024 Objective
Slide 56: IMA401 Demonstrates Anti-Tumor Activity
56 *Patients in this analysis are part of the efficacy analysis set with at least one post - treatment tumor assessment and had received IMA401 infusions at ≥1 mg and showed MAGEA4/8 target expression higher than the MAGEA4/8 qPCR threshold (n=17); Confirmed ORR (cORR): Confirmed objective response
Slide 57: Clinical Activity in Heavily Pre-Treated Cancer Patients
Clinical Activity in Heavily Pre - Treated Cancer Patients 57 CT and MRI scans courtesy of treating physicians (Dr. Manik Chatterjee, University Hospital Wuerzburg and Dr. Max - Felix Häring, Eberhard Karls University Tuebingen); HNSCC: Head and neck squamous cell carcinoma; NET CUP: Neuroendocrine
Slide 58: First-in-human Data of IMA401 TCER Targeting MAGEA4/8
First - in - human Data of IMA401 TCER® Targeting MAGEA4/8 Presentation at ESMO on September 16, 2024 • Tolerability : Most common treatment - related AEs are low - grade CRS, transient lymphopenia and neutropenia • Pharmacokinetics : Median terminal half - life of 16.9 days supporting potential fur
Slide 59: TCER IMA402 Targeting PRAME
TCER® IMA402 Targeting PRAME 59
Slide 60: IMA402 – Efficacy Assessment in vitro
TCER® IMA402 Targeting PRAME – Efficacy Assessment in vitro Tumor Cell Killing at Low Physiological PRAME Peptide Levels 60 140 120 100 80 60 40 20 0 ~50 PRAME CpCs 0 140 120 100 80 60 40 20 0 10 - 1 10 0 10 1 10 2 10 3 10 4 10 5 IMA402 [pM] Cytotoxicity [%] Target - negative 0 140 120 100 80 60 40
Slide 61: IMA402 Achieves Durable Tumor Control of Large Tumors in vivo
TCER® IMA402 Achieves Durable Tumor Control of Large Tumors in vivo 61 • Dose - dependent efficacy of IMA402 in cell line - derived in vivo mouse model • Durable shrinkage of large tumors including complete responses over prolonged period • Sufficiently high drug doses are key to achieving desired a
Slide 62: Half-life Extended Format of IMA402
Half - life Extended Format of IMA402 Confers Terminal Half - life of >1 Week 62 pHLA – aFc Assay pHLA – aV L Assay • IMA402 shows a terminal serum half - life of ≈ 8 days in mice • IMA402 will be initially dosed weekly in the clinical trial • Dosing frequency may be adapted based on clinical data I
Slide 63: Phase 1/2 Clinical Trial to Evaluate TCER IMA402
Phase 1/2 Clinical Trial to Evaluate TCER® IMA402 Targeting PRAME First Clinical Data Planned in 2H 2024 63 Phase 1: Dose Escalation Phase 2a: Dose Expansion Adaptive design aimed at accelerating dose escalation • Specific indications plus ongoing basket • Combination therapies • Optional dose/appli
Slide 64: Immatics' Proprietary Target and TCR Discovery Platforms
Immatics’ ro ri tary arg t an Discov ry latforms 64
Slide 65: Our TCR-based Approaches Leverage the Full Target Space
Our TCR - based Approaches Leverage the Full Target Space beyond the Cancer Cell Surface 65 Technology
Slide 66: True Cancer Targets & Matching Right TCRs
True Cancer Targets & Matching Right TCRs Goal to Maximize Anti - Tumor Activity and Minimize Safety Risks of TCR - based Immunotherapies 66 True Targets via XPRESIDENT® technology platform • are naturally presented on tumor tissues as identified by mass - spec • are absent or presented at only low
Slide 67: Pool of Prioritized Targets: XPRESIDENT Target Platform
Technology Pool of 200 Prioritized Targets as Foundation for Future Value Generation XPRESIDENT® Target Platform 67 200 Prioritized Targets Grouped in 3 Target Classes: 1. Well known and characterized parent protein (20%) e.g. MAGE family cancer testis antigens 2. Unknown or poorly characterized par
Slide 68: Potential for Large Patient Populations across Multiple Solid Cancers
Potential for Large Patient Populations across Multiple Solid Cancers 68 Uterine Carcinoma – 97% Uterine Carcinosarcoma – 100% Sarcoma Subtypes – up to 100% Cut. Melanoma – 95% Uveal Melanoma 1 – 89% Ovarian Carcinoma – 84% Squamous NSCLC – 68% TNBC – 63% Small Cell Lung Cancer – 45% Kidney Carcinom
Slide 69: Identification of the Most Relevant Target: MAGEA4/8 Example
Immatics’ Uniqu a ability – Identification of the most Relevant Target Example of MAGEA4/8 Peptide Target 69 1 Copy number per tumor cell (CpC) measured on a paired - sample basis by AbsQuant®, i.e. comparing MAGEA4 vs. MAGEA4/A8 peptide presentation on same sample, 2 Students paired T test p<0.001
Slide 70: Development of the Right TCR – XCEPTOR Technology
Development of the Right TCR – XCEPTOR® Technology TCR Discovery and Engineering for ACT and TCR Bispecifics 70 TCR Bispecifics T cell engaging receptor (TCER®) Adoptive Cell Therapy A C T e n g in e ® ACTallo® • Fast, efficient and highly sensitive discovery of highly specific, natural TCRs • Prote
Slide 71: Optimal Target Selection & TCR Specificity for Minimizing Safety Risks
Optimal Target Selection & TCR Specificity for Minimizing Safety Risks Unique Interplay between Technology Platforms Allows Early De - risking for Clinical Development 71 Target peptide presented on tumor cells Selective killing of tumor cells Target peptide presented on normal cells Of f - t a r ge
Slide 72: Bioinformatics and AI-Platform XCUBE
“ I Is Wh r th Data Is®” Bioinformatics and AI - Platform XCUBE 72 Data Engineering Development of data warehouses & user interfaces Data Science Development of statistical & machine learning models Data Processing Processing of mass - spec & next - gen sequencing data 1 THE RA PE U TIC KNOWLEDGE XP
Slide 73: Robust Intellectual Property Portfolio
Immatics’ obust Int ll ctual ro rty ortfolio Protection Strategy of Key Assets in Major Markets and Beyond 73 Technologies T ar g e ts T CRs T C ER® Th e r ap e u t ic Uses Cell Therapy TCRs with high affinity and specificity profile Differentiated technologies, platforms and assays for Target Resea
Slide 74: ACTengine IMA204 – TCR-T Targeting COL6A3 Exon 6
ACTengine® IMA204 – TCR - T Targeting COL6A3 Exon 6 74
Slide 75: ACTengine IMA204 First-in-Class TCR-T Targeting Tumor Stroma
ACTengine® IMA204 First - in - Class TCR - T Targeting Tumor Stroma Key Features 75 HLA - A*02 - presented peptide derived from COL6A3 exon 6 Naturally and specifically presented on tumors at high target density 1 : 100 - 700 copies/cell Novel tumor stroma target identified and validated by XPRESIDE
Slide 76: IMA204 – High Affinity, CD8-independent TCR
ACTengine® IMA204 – High Affinity, CD8 - independent TCR Complete Tumor Eradication in vitro & in vivo 1 by Affinity - enhanced IMA204 TCR CD8 - independent TCR leads to tumor eradication in all mice treated 76 W Si Do ild t ngl ub l y pe e m e m utan u t a n t t T u No mo n - t r ce ran lls o s duc
Slide 77: ACTallo – Our Next-generation Off-the-shelf TCR-T
ACTallo® – Our Next - generation Off - the - shelf TCR - T 77
Slide 78: ACTallo – Immatics' Allogeneic Cell Therapy Approach
ACTallo® – Immatics’ llog n ic ll h ra y roach • Off - the - shelf cell therapy , no need for personalized manufacturing reduced logistics and time to application • Potential for hundreds of doses from one single donor leukapheresis lower cost of goods • Use of healthy donor material provides st
Slide 79: Why γδ T Cells?
Why γδ c lls? γδ T cells Are Well Suited for an Off - the - shelf Cell Therapy Approach 79 γδ T cells x are abundant in the peripheral blood x show intrinsic anti - tumor activity x naturally infiltrate solid tumors & correlate with favorable prognosis x are HLA - independent, thus do not cause graf
Slide 80: Corporate Information & Milestones
Corporate Information & Milestones 80
Slide 81: Experienced Global Leadership Team
Harpreet Singh Chief Executive Officer Co - Founder >20 yrs biotech experience Arnd Christ Chief Financial Officer >20 yrs biotech experience (InflaRx, Medigene, NovImmune, Probiodrug) Carsten Reinhardt Chief Development Officer >20 yrs pharma & biotech experience (Micromet, Roche, Fresenius) Cedrik
Slide 82: Strong, Focused and Highly Integrated Trans-Atlantic Organization
Strong, Focused and Highly Integrated Trans - Atlantic Organization 82 Houston, Texas ~205 FTEs Cell therapy development & manufacturing Munich, Germany ~85 FTEs Various operating functions Tübingen, Germany ~255 FTEs Target & TCR discovery and TCR Bispecifics d ev elopm e nt Corporate FTEs as of Ju
Slide 83: Delivering the Power of T cells to Cancer Patients
Deli v ering the Power of T cells to Cancer Patients © Immatics. Not for further reproduction or distribution. www.immatics.com